Rolando Ania, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,570, 6.2 times the $415 reported in 2019.
Across 403 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- Neurocrine Biosciences, Inc.$877
- Pfizer$553
- SK Life Science, Inc.$535
- Lilly USA, LLC$472
- plus $3K from 26 others
Across 1 payment — averaging $2636.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$3K
What the payments were for
- Speaking & faculty fees$160%
- Food & beverage$8,48499%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,509 |
| UCB, Inc. | 68 | $1,186 |
| Neurocrine Biosciences, Inc. | 35 | $877 |
| Pfizer | 36 | $553 |
| SK Life Science, Inc. | 37 | $535 |
| Lilly USA, LLC | 15 | $472 |
| Livanova USA, Inc. | 6 | $406 |
| Catalyst Pharmaceuticals, Inc. | 11 | $306 |
| Greenwich Biosciences, Inc. | 3 | $261 |
| Argenx US, Inc. | 10 | $260 |
| Lundbeck LLC | 11 | $219 |
| Amneal Pharmaceuticals LLC | 8 | $212 |
| Impel Pharmaceuticals Inc. | 14 | $208 |
| Neurelis, Inc. | 8 | $202 |
| Jazz Pharmaceuticals Inc. | 8 | $174 |
| AstraZeneca(2 entities) | 5 | $170 |
| Sumitomo Pharma America, Inc. | 9 | $164 |
| Tanabe Pharma America, Inc. | 7 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Eisai Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Biogen | 2 | $49 |
| Grifols USA, LLC | 2 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| MDD US Operations, LLC | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,529 in reported general payments places this provider in the 70th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 39 | $653,041 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 47 | $598,130 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $149,153 |
| EpidiolexCannabidiol (Cbd) | 13 | $72,556 |
| BriviactBrivaracetam | 47 | $71,109 |
| XcopriCenobamate | 42 | $46,648 |
| Lacosamide | 20 | $8,457 |
| Pyridostigmine Bromide | 17 | $3,567 |
| Dantrolene Sodium | 32 | $3,101 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 106 | $1,890 |
| Gabapentin | 124 | $1,600 |
| Zonisamide | 23 | $1,350 |
| Divalproex Sodium ErDivalproex Sodium | 49 | $1,302 |
| Levetiracetam ErLevetiracetam | 15 | $1,109 |
| Levetiracetam | 44 | $926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $42 | $149,15324 claims |
| UCB, Inc.Briviact | $1,186 | $71,10947 claims |
| SK Life Science, Inc.Xcopri | $535 | $46,64842 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $212 | $3,56717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 145 neurology providers in Nevada.
Other neurology in Reno
- Melissa BlochReno$883K
- Burton TabaacReno$287K
- G BigleyReno$133K
- Lee GerwitzReno$88K
- Verena SamaraReno$64K
- Frank QuaglieriReno$21K
- Timothy LouieReno$15K
- Yen-Yi PengReno$14K
- Danny TruongReno$12K
- Byung Chan AhnReno$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.